Non-small cell lung carcinoma (not otherwise specified) rates are not solely influenced by pathologists’ decisions on the use of immunohistochemistry.

Gavin Chapman; David Dorward; Christopher Lucas; William Wallace

doi:10.1111/his.13074

Non-small cell lung carcinoma (not otherwise specified) rates are not solely influenced by pathologists’ decisions on the use of immunohistochemistry.

Gavin Chapman, David Dorward, Christopher Lucas, William Wallace

Research output: Contribution to journal › Article › peer-review

Abstract

With increasing focus on the molecular classification of non-small cell lung cancers (NSCLC) to guide therapeutic decisions the correct application of appropriate diagnostic tools is paramount. In small biopsy and cytology specimens the majority can be accurately subtyped on their morphological appearances or with the use of additional immunohistochemistry (IHC), namely thyroid transcription factor-1 (TTF-1) and p63 and/or p40.(1) Despite this, there is still a small proportion in which sub-classification is not possible therefore the category "not otherwise specified" (NSCLC-NOS) remains valid. This can be the result of a 'null' IHC phenotype but can also occur in specimens where there are poorly differentiated malignant cells but insufficient material for subsequent IHC.

Original language	English
Journal	Histopathology
Volume	70
Issue number	3
Early online date	3 Sept 2016
DOIs	https://doi.org/10.1111/his.13074
Publication status	Published - Feb 2017

Access to Document

10.1111/his.13074

Non-small cell lung carcinoma (not otherwise specified) rates are not solely influenced by pathologists’ decisions on the use of immunohistochemistry.
Author's final peer-reviewed manuscript as accepted for publication.
Accepted author manuscript, 45.9 KB

Cite this

@article{5ab3cae82a2e4125baaaea0b8d27f483,

title = "Non-small cell lung carcinoma (not otherwise specified) rates are not solely influenced by pathologists{\textquoteright} decisions on the use of immunohistochemistry.",

abstract = "With increasing focus on the molecular classification of non-small cell lung cancers (NSCLC) to guide therapeutic decisions the correct application of appropriate diagnostic tools is paramount. In small biopsy and cytology specimens the majority can be accurately subtyped on their morphological appearances or with the use of additional immunohistochemistry (IHC), namely thyroid transcription factor-1 (TTF-1) and p63 and/or p40.(1) Despite this, there is still a small proportion in which sub-classification is not possible therefore the category {"}not otherwise specified{"} (NSCLC-NOS) remains valid. This can be the result of a 'null' IHC phenotype but can also occur in specimens where there are poorly differentiated malignant cells but insufficient material for subsequent IHC. ",

author = "Gavin Chapman and David Dorward and Christopher Lucas and William Wallace",

year = "2017",

month = feb,

doi = "10.1111/his.13074",

language = "English",

volume = "70",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Non-small cell lung carcinoma (not otherwise specified) rates are not solely influenced by pathologists’ decisions on the use of immunohistochemistry.

AU - Chapman, Gavin

AU - Dorward, David

AU - Lucas, Christopher

AU - Wallace, William

PY - 2017/2

Y1 - 2017/2

N2 - With increasing focus on the molecular classification of non-small cell lung cancers (NSCLC) to guide therapeutic decisions the correct application of appropriate diagnostic tools is paramount. In small biopsy and cytology specimens the majority can be accurately subtyped on their morphological appearances or with the use of additional immunohistochemistry (IHC), namely thyroid transcription factor-1 (TTF-1) and p63 and/or p40.(1) Despite this, there is still a small proportion in which sub-classification is not possible therefore the category "not otherwise specified" (NSCLC-NOS) remains valid. This can be the result of a 'null' IHC phenotype but can also occur in specimens where there are poorly differentiated malignant cells but insufficient material for subsequent IHC.

AB - With increasing focus on the molecular classification of non-small cell lung cancers (NSCLC) to guide therapeutic decisions the correct application of appropriate diagnostic tools is paramount. In small biopsy and cytology specimens the majority can be accurately subtyped on their morphological appearances or with the use of additional immunohistochemistry (IHC), namely thyroid transcription factor-1 (TTF-1) and p63 and/or p40.(1) Despite this, there is still a small proportion in which sub-classification is not possible therefore the category "not otherwise specified" (NSCLC-NOS) remains valid. This can be the result of a 'null' IHC phenotype but can also occur in specimens where there are poorly differentiated malignant cells but insufficient material for subsequent IHC.

U2 - 10.1111/his.13074

DO - 10.1111/his.13074

M3 - Article

C2 - 27591577

SN - 0309-0167

VL - 70

JO - Histopathology

JF - Histopathology

IS - 3

ER -

Non-small cell lung carcinoma (not otherwise specified) rates are not solely influenced by pathologists’ decisions on the use of immunohistochemistry.

Abstract

Access to Document

Fingerprint

Cite this